GI
BPMC

GAMMA Investing’s Blueprint Medicines BPMC Stock Holding History

GAMMA Investing’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-250
Closed -$32K – 3858
2025
Q2 		$32K Sell
250
-76
-23% -$7.89K ﹤0.01% 2210
2025
Q1 		$28.9K Buy
326
+87
+36% +$8.49K ﹤0.01% 2181
2024
Q4 		$20.8K Buy
239
+52
+28% +$4.76K ﹤0.01% 2247
2024
Q3 		$17.3K Buy
187
+1
+0.5% +$99 ﹤0.01% 2190
2024
Q2 		$20K Buy
186
+62
+50% +$6.21K ﹤0.01% 1851
2024
Q1 		$11.8K Buy
124
+27
+28% +$2.32K ﹤0.01% 1972
2023
Q4 		$7.71K Buy
+97
New +$6.29K ﹤0.01% 2038

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GAMMA Investing's BPMC Position: Q3 2025 in Review

GAMMA Investing sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 250 shares — an estimated $32K sold.

GAMMA Investing first reported a position in BPMC in Q4 2023 and held it in 7 quarters. The position peaked at $32K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • GAMMA Investing reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • GAMMA Investing sold 250 Blueprint Medicines shares in Q3 2025, an estimated $32K.
  • GAMMA Investing first reported a position in Blueprint Medicines in Q4 2023 and held it in 7 quarters.
  • GAMMA Investing's Blueprint Medicines position peaked at $32K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on GAMMA Investing's 13F filing for Q3 2025, filed 2 Oct 2025.